Alterity Therapeutics Ltd SEC filings ATHE
Alterity Therapeutics Ltd has 1,000 filings in SEC EDGAR's recent list, going back to Oct 22, 2007. Its latest annual report, Form 20-F, was filed on Aug 28, 2026 for the period ended Jun 30, 2026. The most recent current report (Form 6-K) was filed on Oct 30, 2026. The company's fiscal year ends on June 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Sep 8, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Sep 8, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Jun 23, 2026 | Jun 15, 2026 |
| 4 | Insider transaction | Jun 23, 2026 | Jun 15, 2026 |
| 3 | Initial insider ownership | Apr 29, 2026 | Apr 17, 2026 |
| 3 | Initial insider ownership | Apr 15, 2026 | Apr 15, 2026 |
| 3 | Initial insider ownership | Apr 10, 2026 | Apr 10, 2026 |
| 3 | Initial insider ownership | Apr 10, 2026 | Apr 10, 2026 |
| 3 | Initial insider ownership | Apr 10, 2026 | Apr 10, 2026 |
| 3 | Initial insider ownership | Apr 9, 2026 | Apr 9, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 5, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 2, 2025 | — |
| SC 13D/A | Amended ownership over 5% (active) | Oct 31, 2022 | — |
| SC 13D/A | Amended ownership over 5% (active) | Aug 26, 2022 | — |
| SC 13D/A | Amended ownership over 5% (active) | Aug 1, 2022 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jul 21, 2022 | — |
| SC 13D/A | Amended ownership over 5% (active) | Mar 28, 2022 | — |
| SC 13D/A | Amended ownership over 5% (active) | Mar 4, 2022 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jul 8, 2021 | — |
| SC 13D/A | Amended ownership over 5% (active) | Nov 25, 2020 | — |
| SC 13D/A | Amended ownership over 5% (active) | Oct 26, 2020 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jul 6, 2020 | — |
| SC 13D/A | Amended ownership over 5% (active) | Dec 23, 2019 | — |
| SC 13D | Ownership over 5% (active) | Apr 18, 2019 | — |
| SC 13G | Ownership over 5% (passive) | Apr 1, 2011 | — |
| SC 13G | Ownership over 5% (passive) | Mar 25, 2011 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2011 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 6, 2011 | — |
| SC 13G/A | Amended ownership over 5% (passive) | May 18, 2010 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Mar 4, 2010 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 19, 2010 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 12, 2010 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 6, 2010 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 30, 2009 | — |
| SC 13G | Ownership over 5% (passive) | Nov 16, 2009 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 12, 2009 | — |
| SC 13G | Ownership over 5% (passive) | Sep 15, 2009 | — |
Showing 37 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ATHE (Nasdaq), PRNAF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Melbourne
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1131343
- Former names
- PRANA BIOTECHNOLOGY LTD (until Apr 8, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.